Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Reaffirmed as Buy by Chardan Capital

Rocket Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Chardan Capital reaffirmed its Buy rating on Rocket Pharmaceuticals and set an $11 price target, implying 420% upside from the then-current share price.
  • Analyst views are mixed: MarketBeat reported a consensus Hold rating and $7.77 average target, with ratings ranging from Sell to Strong Buy.
  • Shares traded at $2.12, near their one-year low, and the company’s latest quarterly loss of $0.43 per share missed the $0.40 consensus estimate.
  • Interested in Rocket Pharmaceuticals? Here are five stocks we like better.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report)'s stock had its "buy" rating restated by Chardan Capital in a note issued to investors on Tuesday, Benzinga reports. They presently have a $11.00 target price on the biotechnology company's stock. Chardan Capital's price objective indicates a potential upside of 420.09% from the stock's current price.

A number of other equities analysts have also commented on RCKT. Weiss Ratings reissued a "sell (e+)" rating on shares of Rocket Pharmaceuticals in a report on Wednesday, November 4th. Wedbush reissued an "outperform" rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, October 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Rocket Pharmaceuticals in a report on Wednesday, October 7th. Jefferies Financial Group restated a "hold" rating and set a $2.95 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, October 7th. Finally, Needham & Company LLC upgraded Rocket Pharmaceuticals from a "hold" rating to a "buy" rating and set a $9.00 price target on the stock in a research report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $7.77.

Get Our Latest Stock Analysis on Rocket Pharmaceuticals

Rocket Pharmaceuticals Stock Performance

Shares of RCKT stock traded down $0.04 on Tuesday, hitting $2.12. 1,217,511 shares of the stock were exchanged, compared to its average volume of 2,443,024. The company has a current ratio of 9.24, a quick ratio of 9.24 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $232.17 million, a PE ratio of -14.03 and a beta of 0.51. Rocket Pharmaceuticals has a one year low of $2.03 and a one year high of $5.45. The firm's 50 day moving average is $2.68 and its two-hundred day moving average is $3.38.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.03). Sell-side analysts expect that Rocket Pharmaceuticals will post -1.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 75,364 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $3.40, for a total value of $256,237.60. Following the completion of the sale, the general counsel owned 598,489 shares in the company, valued at approximately $2,034,862.60. This trade represents a 11.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 21.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Rocket Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Maverick Capital Ltd. boosted its stake in shares of Rocket Pharmaceuticals by 42.0% during the 1st quarter. Maverick Capital Ltd. now owns 3,567,372 shares of the biotechnology company's stock valued at $12,771,000 after purchasing an additional 1,054,262 shares in the last quarter. Monaco Asset Management SAM purchased a new position in shares of Rocket Pharmaceuticals during the second quarter valued at about $8,483,000. Bank of America Corp DE bought a new position in Rocket Pharmaceuticals in the second quarter worth about $2,512,000. BlackRock Inc. bought a new position in Rocket Pharmaceuticals in the second quarter worth about $33,940,000. Finally, Ieq Capital LLC bought a new position in Rocket Pharmaceuticals in the second quarter worth about $1,506,000. Institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Company Profile

(Get Free Report)

Rocket Pharmaceuticals, Inc. is a biotechnology company developing gene therapies for rare, serious diseases, with a focus on inherited disorders that often affect children. Its research programs use lentiviral and adeno-associated viral (AAV) vector technologies to deliver therapeutic genes to patients' cells. The company's pipeline has included programs targeting conditions such as Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, Danon disease and arrhythmogenic cardiomyopathy.

Featured Articles

Analyst Recommendations for Rocket Pharmaceuticals (NASDAQ:RCKT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?

Before you consider Rocket Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.

While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines